M&A

We work with entrepreneur-owned businesses, private equity-backed companies and large corporates on company sales, acquisitions, mergers and disposals. Our in-depth understanding of our sectors and of the global buyer universe enables us to think creatively about strategic positioning, identify interesting partners, manage complexity and deliver outstanding results. The majority of our deals are cross-border, with a mix of European, North American and Asian clients and counterparties.

Sellers: when the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

And for buyers: our global network and local presence, together with a deep analysis of evolving sector trends, opens up a plethora of opportunities to expand your reach — and outpace the competition.

M&A Deals

Jul 2022
has received investment from
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF
Apr 2022
has been acquired by
Mar 2022
An AlbionVC-backed company
has received investment from
Morgan Stanley Expansion Capital and Keyhaven Capital Partners co-invest
Mar 2022
has received investment from
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility

Results. Great people creating great outcomes, together.

Latest Insights

Reports
27th September 2022

Pharma Commercialisation Services Update – September 2022

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector.  As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]

Insights
8th September 2022

Pharma Licensing: the why, the how and a few things to get right!

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Insights
8th September 2022

Global skills shortages fuel innovative HRTech solutions

The HRTech sector is more active than it has ever been before with the pandemic accelerating the adoption of technology across all HR processes. No longer seen as an administrative function, HR is now viewed as a strategic business unit focusing on the mission critical challenge of identifying and recruiting top talent but also retaining […]